" class="no-js "lang="en-US"> James M. Mackay - Medtech Alert
Thursday, March 28, 2024
James M. Mackay

James M. Mackay

About James M. Mackay

Distinguished scientist and global life sciences business leader with strong record of bringing multiple drugs to market and patients

|| Strategic thinker with ability to define and implement strategic vision through clear communication and innovative operational delivery

|| Develops strategic and operational partnerships, and builds inspiring cultures via authenticity, development of mutual trust, empowerment and mentoring

|| Creates transparent and open environments allowing staff to raise concerns, cultivating deep thinking, and achieving breakthrough results

|| Experience running large pharmaceutical and small biotechnology businesses with ability to work across international boundaries and cultures, enhancing delivery through diversity

|| Value-driven decision making, the courage to make tough decisions to achieve value-added delivery to the business, and a purposefulness and drive to deliver an outcome that creates positive and lasting change

CAREER HIGHLIGHTS

• Led successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca

• Achieved FDA and EMA approval of Zurampic, the first novel MOA for the treatment of gout
in over 50 years

• Led successful commercial licensing of Zurampic and Duzallo to Ironwood Pharmaceuticals and
Grunenthal

• Transformed the AstraZeneca/BMS Diabetes global development and commercial collaboration, and
established Onglyza, Kombiglyze XR and Komboglyze as key growth drivers in the AZ portfolio

• Designed and implemented multiple innovative delivery and partnership models including an
industry leading approach to delivery of outsourced clinical work through development of strategic
partnerships with CROs

• Designed and implemented multiple strategic re-organizations, led major global change
management, whilst delivering improved efficiencies and productivity

Related Story

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer

August 25 2022

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat […]

Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

March 29 2022

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat […]

Aristea Therapeutics Announces Key Leadership Appointments to Advance its Clinical Pipeline

January 14 2022

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat […]

Aristea Appoints Justin Thacker as Chief Financial Officer

August 24 2021

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat […]

Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases

July 28 2021

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat […]